Progress and challenges of confirmatory trials for cancer drugs granted conditional approval in China

被引：0
|
作者：
Luo, Xingxian [1 ]
Xu, Yang [2 ,3 ]
Du, Xin [4 ]
Lv, Xufeng [5 ]
Chen, Si [5 ]
Yang, Yue [2 ,3 ]
Huang, Lin [1 ]
Zhang, Xiaohong [1 ]
机构：
[1] Peking Univ, Dept Pharm, Peoples Hosp, Beijing, Peoples R China
[2] Tsinghua Univ, Sch Pharmaceut Sci, Beijing, Peoples R China
[3] Natl Med Prod Adm, Key Lab Innovat Drug Res & Evaluat, Beijing, Peoples R China
[4] Tsinghua Univ, Vanke Sch Publ Hlth, Beijing, Peoples R China
[5] Natl Med Prod Adm, Ctr Drug Evaluat, Beijing, Peoples R China
来源：
LANCET REGIONAL HEALTH-WESTERN PACIFIC | 2024年 / 52卷
基金：
中国国家自然科学基金;
关键词：
SURVIVAL; ONCOLOGY;
D O I：
10.1016/j.lanwpc.2024.101238
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] REPORTING OF CARDIOVASCULAR EVENTS IN CLINICAL TRIALS SUPPORTING FDA-APPROVAL OF CONTEMPORARY CANCER DRUGS
    Addison, Daniel
    Bonsu, Janice
    Charles, Lawrence
    Guha, Avirup
    Baker, Brandee
    Woyach, Jennifer
    Awan, Farrukh
    Rogers, Kerry
    Lustberg, Maryam
    Reinbolt, Raquel
    Brammer, Jonathan
    Miller, Eric
    Jneid, Hani
    Paskett, Electra
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 1879 - 1879
  • [42] Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs
    Agrawal, Mukta
    Saraf, Swarnlata
    Saraf, Shailendra
    Antimisiaris, Sophia G.
    Chougule, Mahavir Bhupal
    Shoyele, Sunday A.
    Alexander, Amit
    JOURNAL OF CONTROLLED RELEASE, 2018, 281 : 139 - 177
  • [43] Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs
    Michaeli, Daniel Tobias
    Michaeli, Thomas
    Albers, Sebastian
    Michaeli, Julia Caroline
    TARGETED ONCOLOGY, 2024, 19 (05) : 797 - 809
  • [44] Partial orphan cancer drugs: FDA approval, clinical benefit, trials, epidemiology, price, beneficiaries, and spending
    Michaeli, D. T.
    Michaeli, C. T.
    ANNALS OF ONCOLOGY, 2023, 34 : S927 - S927
  • [45] Do post-approval phase III trials for accelerated approved cancer drugs violate equipoise?
    Lurie, A. J.
    Djulbegovic, B.
    Nebeker, J. R.
    Angelotta, C.
    Gordon, L. I.
    Raisch, D. W.
    Yarnold, P. R.
    Carson, K. R.
    McKoy, J. M.
    Bennett, C. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 307S - 307S
  • [46] Patient enrollment per month (accrual) in clinical trials leading to the FDA approval of new cancer drugs
    Albers, S.
    Michaeli, J. C.
    Michaeli, C. T.
    Michaeli, D. T.
    ANNALS OF ONCOLOGY, 2024, 35 : S527 - S527
  • [47] Fragility index of trials supporting approval of anti-cancer drugs in common solid tumors.
    Desnoyers, Alexandra
    Nadler, Michelle
    Saleh, Ramy
    Amir, Eitan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] Quality evaluation of investigator-initiated trials using post-approval cancer drugs in Japan
    Kondo, Shunsuke
    Hosoi, Hiroko
    Itahashi, Kota
    Hashimoto, Jun
    CANCER SCIENCE, 2017, 108 (05) : 995 - 999
  • [49] Japan's conditional early approval program for innovative cancer drugs: Comparison of the regulatory processes with the US FDA and the EMA
    Murayama, Anju
    Ueda, Munetaka
    Shrestha, Sunil
    Tanimoto, Tetsuya
    Ozaki, Akihiko
    CANCER CELL, 2021, 39 (09) : 1165 - 1166
  • [50] Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development (vol 31, pg 399, 2017)
    Krentz, Andrew J.
    Rodriguez-Araujo, Gerardo
    PHARMACEUTICAL MEDICINE, 2018, 32 (01) : 93 - 93
12345